Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)

被引：1
|
作者：
Hankosky, Emily R.
Desai, Karishma
Chinthammit, Chanadda
Grabner, Michael
Stockbower, Grace
He, Xuanyao
Mojdami, Donna
Wenziger, Cachet
Gibble, Theresa Hunter
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-2084-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2084-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)
    Mody, Reema
    Desai, Karishma
    Teng, Chia-Chen
    Reznor, Gally
    Stockbower, Grace
    Grabner, Michael
    Benneyworth, Brian D.
    DIABETES, 2024, 73
  • [2] Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States
    Hankosky, Emily R.
    Desai, Karishma
    Chinthammit, Chanadda
    Grabner, Michael
    Stockbower, Grace
    He, Xuanyao
    Mojdami, Donna
    Wenziger, Cachet
    Gibble, Theresa Hunter
    DIABETES & METABOLISM, 2025, 51 (03)
  • [3] Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
    Hankosky, Emily R.
    Chinthammit, Chanadda
    Meeks, Alexandra
    Huang, Ahong
    Ward, Jennifer M.
    Mojdami, Donna
    Gibble, Theresa Hunter
    DIABETES OBESITY & METABOLISM, 2025, 27 (05): : 2810 - 2821
  • [4] REAL-WORLD USE OF TIRZEPATIDE AMONG PEOPLE WITHOUT EVIDENCE OF TYPE 2 DIABETES: RESULTS FROM MERATIVE MARKETSCAN COMMERCIAL DATABASE
    Hunter, T.
    Meeks, A. C.
    Liao, B.
    Ward, J.
    Hankosky, E. R.
    Chinthammit, C.
    VALUE IN HEALTH, 2024, 27 (06) : S395 - S395
  • [5] Type 2 Diabetes (T2D) Prediction by Hemoglobin A1c in Real-World Scenarios
    Leong, Aaron
    Daya, Natalie
    Porneala, Bianca
    Devlin, James J.
    Shiffman, Dov X.
    Mcphaul, Michael J.
    Selvin, Elizabeth
    Meigs, James B.
    DIABETES, 2017, 66 : A418 - A419
  • [6] Real-World Use of Tirzepatide in People With Obesity or Overweight: Merative Claims Database Results
    Gibble, Theresa Hunter
    Chinthammit, Chanadda
    Dimitriadis, Georgios
    Raibulet, Nedina Kalezic
    Huang, Ahong
    Kao, Christi
    Li, Alice
    Schapiro, David
    Hankosky, Emily
    OBESITY, 2024, 32 : 184 - 184
  • [7] Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database
    Gibble, Theresa Hunter
    Chinthammit, Chanadda
    Ward, Jennifer M.
    Cappell, Katherine
    Sedgley, Robert
    Bonafede, Machaon
    Liao, Birong
    Hankosky, Emily R.
    DIABETES OBESITY & METABOLISM, 2025,
  • [8] Tirzepatide versus Semaglutide 2.4 mg for People with Obesity or Overweight and Type 2 Diabetes
    Hankosky, Emily
    Brumm, Julia Fraseur
    Malik, Raleigh
    Niemeyer, Anthony
    Wang, Fangyu
    Zhang, Xiaotian Michelle
    He, Xuanyao
    OBESITY, 2023, 31 : 83 - 84
  • [9] Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus
    Al Zweihary, Ali M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [10] Tirzepatide and MASLD: Real-World Outcomes in Patients With Overweight and Obesity
    Espinosa, Maria A.
    Fansa, Sima
    Anazco, Diego
    Ghusn, Wissam
    Elif, Tama
    Cifuentes, Lizeth
    Alejandro, Campos
    Rivera, Rene
    Hurtado, Maria D.
    Acosta, Andres
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1513 - S1514
12345